ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting

    Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis

    J. Madison Hyer1, Bethany Wolf1, Jim Oates2, Gary S. Gilkeson3 and Diane L. Kamen2, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Department of Rheumatology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…
  • Abstract Number: 394 • 2015 ACR/ARHP Annual Meeting

    Clinical Features of Children with Silent Lupus Nephritis

    Hiroyuki Wakiguchi1, Syuji Takei2,3, Tomohiro Kubota1, Yuichi Yamasaki1, Tsuyoshi Yamatou1, Yasuhito Nerome1, Harumi Akaike1, Yukiko Nonaka1, Tomoko Takezaki1, Hiroyuki Imanaka1 and Yoshifumi Kawano1, 1Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, 2School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 3Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshma, Japan

    Background/Purpose: Lupus nephritis (LN) is the major findings in systemic lupus erythematosus (SLE). LN with some pathologic findings in the kidney but had normal urine…
  • Abstract Number: 403 • 2015 ACR/ARHP Annual Meeting

    Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?

    Justin Hung Tiong Tan1, Sook Fun Hoh2, Manasita Tanya1, Lena Das1, Ma Thin Mar Win3, Yiong Huak Chan3 and Thaschawee Arkachaisri1,4, 1Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 2Nursing, KK Women's and Children's Hospital, Singapore, Singapore, 3Biostatistics Unit, Yong Loo Lin School of Medicine, Singapore, Singapore, 4Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore

    Background/Purpose: The time to recovery from proteinuria in patients with lupus nephritis (LN) receiving standard treatment has been described in adult, but not in children.…
  • Abstract Number: 754 • 2015 ACR/ARHP Annual Meeting

    Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide

    Alexandra Audemard-Verger1, Nicolas Martin Silva2, Céline Verstuyft3, Nathalie Costedoat-Chalumeau4, Aurélie Hummel5, Véronique Le Guern4, Karim Sacre6, Olivier Meyer7, Eric Daugas8, Cecile Goujard9, Audrey Sultan2, Thierry Lobbedez2, Lionel Galicier10, Jacques Pourrat11, Claire Le Hello2, Michel Godin12, Remy Morello2, Marc Lambert13, Eric Hachulla13, Philippe Vanhille14, Guillaume Queffeulou15, Jacques Potier15, Jean Jacques Dion16, P Bataille17, Dominique Chauveau18, Guillaume Moulis19, Dominique Farge20, Pierre Duhaut21, Bernadette Saint Marcoux22, Alban Deroux23, Jennifer Manuzak24, Camille Francès25, Olivier Aumaître26, Holy Bezanahary27, Laurent Becquemont28 and Boris Bienvenu29, 1Internal Medicine, CHU Caen, caen, France, 2CHU Caen, caen, France, 3Pharmacology, Hopital Bicêtre, Le Kremlin Bicêtre, France, 4Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 5Necker, paris, France, 6Internal Medicine, Hospital Bichat, Paris, France, 7Rheumatology, Hopital Bichat, Paris, France, 8Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, 9Bichat, Paris, France, 10Clinical Immunology, St Louis Hospital, Paris, France, 11Nephrology, Rangeuil Hospital, Paris, France, 12CHU Rouen, Rouen, France, 13CHU Lille, Lille, France, 14Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, Valenciennes, France, 15Ch Cherbourg, Cherbourg, France, 16Ch Charleville Mezeiere, Charleville Mezeiere, France, 17Ch Boulogne sur Mer, Boulogne sur Mer, France, 18CH Toulouse, Toulouse, France, 19CHU Purpan, Toulouse, France, 20Internal Medicine, Hopital St Louis, Paris, France, 21Department of Internal Medicine and RECIF, CHU Amiens, Amiens, France, 22CH Aulnay sous Bois, Aulnay sous Bois, France, 23Internal Medicine, CHU Grenoble, Grenoble, France, 24Institut Cochin, Paris, France, 25Dermatology Service, Tenon Hospital, Paris, France, 26Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 27Internal Medicine, University Hospital of Limoges, Limoges, France, 28KB, Paris, France, 29Internal Medicine, Hospital Caen, Caen, France

    Background/Purpose: Cyclophosphamide (CYC) is effective in inducing remission of lupus nephritis (LN). CYC, as a pro-drug, requires bioactivation through multiple hepatic cytochrome P450s and glutathione…
  • Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting

    Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis

    Anna R. Broder1, Candace H. Feldman2, Anand Kumthekar3, Michail Alevizos4, Hongshu Guan5, Medha Barbhaiya6 and Karen H. Costenbader7, 1Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 4Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6Internal Medicine, Weill Cornell Medical College, New York, NY, 7Rheumatology, Brigham & Women's Hospital, Boston, MA

    Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…
  • Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting

    Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis

    Jeffrey Hampton1, Nicholas A. Young2, Sudha Agarwal3, Saba Aqel3, Kendra Jones3, Lai-Chu Wu2,4, Nicole Powell5, John Sheridan5, Michael Bruss3 and Wael N. Jarjour2, 1Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 3Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 4Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, 5Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose:  Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage.  Our group has previously shown that moderate daily exercise reduces systemic inflammation…
  • Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting

    Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

    Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea

    Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
  • Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting

    Real Life Implementation of Lupus Nephritis Randomized Controlled Trials

    Angela Pakozdi1, Ravindra Rajakariar2, Muhammad Magdi Yaqoob2 and Dev Pyne1, 1Rheumatology, Barts Health NHS Trust, London, United Kingdom, 2Renal Medicine, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
  • Abstract Number: 1814 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients

    Jin Young Moon, Hyun Mi Kwon, Eun Young Ahn, Jin Kyun Park, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Background/Purpose: Treatment of lupus nephritis requires aggressive immunosuppressive drugs which includes high dose glucocorticoids. Immunosuppressive treatment is a risk factor for opportunistic infections such as…
  • Abstract Number: 2016 • 2015 ACR/ARHP Annual Meeting

    Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging

    Premasany Kanapathippillai, Sayed Esmaeil Dorraji and Kristin A Fenton, RNA and Molecular Pathology, UIT, The Artic University of Norway, Tromso, Norway

    Background/Purpose: The formation of tertiary lymphoid structures (TLS) are known to occur during the development of several diseases, including systemic lupus erythematosus (SLE), but in…
  • Abstract Number: 2508 • 2015 ACR/ARHP Annual Meeting

    Adherence to ACR Guidelines in the Management of Lupus Nephritis – a Quality Improvement Initiative

    Erik Anderson1, Matthew Abramson1, Sanjay Godhwani2, Yaqi Xue3, Jie Yang3 and Heidi Roppelt4, 1Internal Medicine, Stony Brook Hospital, Stony Brook, NY, 2Medicine/Rheumatology, Stony Brook Medicine, Setauket, NY, 3Stony Brook University, Stony Brook, NY, 4Rheumatology, SUNY Stony Brook Unversity Hospital, East Setauket, NY

    Background/Purpose:   Lupus nephritis not only decreases survival, but also its costs are substantial, likely due in part to deficits in care (Carls et al.,…
  • Abstract Number: 2900 • 2015 ACR/ARHP Annual Meeting

    Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis

    Amy Sandford1, Malvika Gulati2, Ademola Oliatan3, Angela Pakozdi2, Ravindra Rajakariar4, Andrea Cove-Smith4 and Dev Pyne2, 1Barts Health NHS trust, London, United Kingdom, 2Rheumatology, Barts Health NHS Trust, London, United Kingdom, 3Barts Health NHS Trust, London, United Kingdom, 4Renal Medicine, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Recently phospholipase A2 receptor 1 (PLA2R1) has been found to be the antigenic target for primary membranous nephropathy (pMN) (1). Circulating anti-PLA2R1 autoantibody can…
  • Abstract Number: 2905 • 2015 ACR/ARHP Annual Meeting

    Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis

    Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Renal Disease Subcommittee of the American College of Rheumatology (ACR) Ad Hoc Committee on Systemic Lupus Erythematosus (SLE) has recommended the urinary protein level…
  • Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting

    Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study

    John G. Hanly for the Systemic Lupus International Collaborating Clinics1, Aidan O'Keeffe2, Li Su3, Murray B. Urowitz4, Juanita Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha R Bernatsky8, Ann E. Clarke9, Daniel J. Wallace10, Joan T. Merrill11, David A. Isenberg12, Anisur Rahman13, Ellen M. Ginzler14, Paul Fortin15, Dafna D. Gladman4, Jorge Sanchez-Guerrero16, Michelle Petri17, Ian Bruce18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Cynthia Aranow21, Graciela S. Alarcon22, Barri Fessler23, Kristjan Steinsson24, Ola Nived25, Gunnar Sturfelt25, Susan Manzi26, Munther A. Khamashta27, Ronald F. van Vollenhoven28, Asad Zoma29, Manuel Ramos-Casals30, Guillermo Ruiz-Irastorza31, S. Sam Lim32, Thomas Stoll33, Murat Inanc34, Kenneth C. Kalunian35, Diane L. Kamen36, Peter Maddison37, Christine A. Peschken38, Søren Jacobsen39, Anca Askanase40, Jill P. Buyon41, Chris Theriault42, Kara Thompson42 and Vernon Farewell3, 1Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, 2MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, 6Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, 9Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 10Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 11Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 13Centre for Rheumatology Research, University College London, London, United Kingdom, 14Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, 15Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, 16Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 17Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 18Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 19Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 20Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, 21Feinstein Institute for Medical Research, Mahasset, NY, 22Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 23Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 24Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, 25Department of Rheumatology, University Hospital Lund, Lund, Sweden, 26Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 27Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 28Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 29Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 30Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 31Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 32Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 33Kantonsspital Geissbergstr, Schaffhausen, Switzerland, 34Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 35UCSD School of Medicine, La Jolla, CA, 36Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 37Ysbyty Gwynedd Bangor, North Wales, United Kingdom, 38Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 39Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 40Columbia University Medical Center, New York, NY, 41Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 42Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…
  • Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting

    Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study

    Javier Merayo-Chalico1, Elia Apodaca2, Ana Barrera-Vargas3, Jorge Alcocer-Varela3 and Diana Gómez-Martín3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose:  Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology